CLAIM #36897 · Eli Lilly and Company (LLY) · 2024Q3 earnings call · Oct 30, 2024 · due Dec 31, 2024
“We are pleased to share that we expect U.S. regulatory action for tirzepatide in adults with obesity and obstructive sleep apnea yet this year.”
Dr. Dan Skovronsky · Chief Scientific Officer
PENDING
graded after results covering Dec 31, 2024 are reported
Verify independently
SEC filings for LLY ↗ · Claim quote is verbatim from the 2024Q3 earnings call.